EBR Systems (EBR) AGM 2026 summary

Opening remarks and agenda

• Meeting opened with confirmation of quorum and introduction of board members and executives.

• The agenda followed the Notice of Meeting, with voting procedures and eligibility explained.

Financial performance review

• Exceeded all 2025 major clinical, regulatory, and reimbursement milestones, including FDA approval and CMS reimbursement at a premium price point.

• Early commercial traction demonstrated with increasing physician engagement, purchasing contracts, and treated patients from Q2'25 through Q1'26.

• Limited Market Release phase initiated in Q4'25, reinforcing a repeatable sales model and significant demand.

• Key performance indicators for Q1 2026 were pre-released, highlighting hospital contract signings as a leading indicator.

• Annual financial statements for the year ended December 31, 2025, were presented for consideration.

Board and executive committee updates

• Directors and executives introduced, highlighting their diverse expertise in product development, commercialization, and scaling early-stage technology.

• Re-election of John McCutcheon and Dr. Bronwyn Evans as directors was proposed and supported by the board.